Journal article
A Phase II Trial of JM-216 in Cervical Cancer: An NCIC CTG Study
Abstract
OBJECTIVE: BMS-182751 (JM-216) is an orally bioavailable platinum compound with activity in platinum-sensitive and platinum-resistant preclinical models. The objective was to determine its activity in recurrent/metastatic squamous cell carcinoma of the cervix.
METHODS: We conducted a phase II study of BMS-182751 given at a dose of 30 mg/m(2) daily for 14 days every 5 weeks.
Authors
Trudeau M; Stuart G; Hirte H; Drouin P; Plante M; Bessette P; Dulude H; Lebwohl D; Fisher B; Seymour L
Journal
Gynecologic Oncology, Vol. 84, No. 2, pp. 327–331
Publisher
Elsevier
Publication Date
February 2002
DOI
10.1006/gyno.2001.6409
ISSN
0090-8258